<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00652288</url>
  </required_header>
  <id_info>
    <org_study_id>403026582</org_study_id>
    <secondary_id>JDRF Hypoglycemia Grant</secondary_id>
    <nct_id>NCT00652288</nct_id>
  </id_info>
  <brief_title>Evaluation of Pharmacokinetics and Pharmacodynamic Properties of Rapid-Acting Insulin Analogs</brief_title>
  <acronym>PK/PD</acronym>
  <official_title>Evaluation of Pharmacokinetic and Pharmacodynamic Properties of Rapid-Acting Insulin Analogs Given as a Bolus by Continuous Subcutaneous Insulin Infusion (CSII) and in MDI Basal-Bolus Therapy in Pediatric Subjects With Type 1 Diabetes (TID)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yale University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Yale University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to evaluate the variations in pharmacokinetic and pharmacodynamic&#xD;
      properties of rapid-acting insulin analogs when given as a bolus by subcutaneous insulin&#xD;
      infusion pump as typically encountered in the care of children with type 1 diabetes.&#xD;
&#xD;
      The specific factors under investigation are:&#xD;
&#xD;
        -  the effects of puberty&#xD;
&#xD;
        -  type of insulin analog&#xD;
&#xD;
        -  site of catheter insertion&#xD;
&#xD;
        -  and age of catheter&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The aim of this study is to evaluate the variations in pharmacokinetic (as determined by&#xD;
      serum free insulin concentrations) and pharmacodynamic (as determined by the glucose infusion&#xD;
      rate required to maintain euglycemia during a euglycemic clamp) properties of the rapid&#xD;
      acting insulin analogs when given as a bolus by subcutaneous insulin infusion pump as&#xD;
      typically encountered in the care of children with type 1 diabetes. The specific factors we&#xD;
      will investigate are the effects of puberty (pre- vs. pubertal), type of insulin analog&#xD;
      (lispro or aspart insulin), site of catheter insertion (gluteal vs. abdominal), and age of&#xD;
      catheter (fresh insertion vs. three-day duration) Our hypotheses are that the peak (Imax) and&#xD;
      area under the curve (IAUC) serum free insulin concentration, and the peak glucose infusion&#xD;
      rate required to maintain euglycemia (GIRmax) and area under the curve (GIRAUC) will vary&#xD;
      based on these conditions, in children given the same weight-based dose.&#xD;
&#xD;
      We will also evaluate the pharmacokinetic and pharmacodynamic properties of Aspart and Lispro&#xD;
      insulin when used in a basal-bolus regimen with insulin Detemir or Glargine, new basal&#xD;
      insulin analogs, given as separate injections and when combined in a single injection in&#xD;
      adolescent patients with Type 1 DM. We hypothesize that the peak (IMAX) and area under the&#xD;
      curve (IAUC) serum insulin concentrations, and the peak glucose infusion rate required to&#xD;
      maintain euglycemia (GIRMAX) and area under the curve (GIRAUC) of the Aspart/Lispro bolus,&#xD;
      will be similar when the Aspart/Lispro is combined in the same syringe with the insulin&#xD;
      Detemir/Glargine, compared to when the Aspart/Lispro and Detemir/Glargine are given as two&#xD;
      separate injections.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2007</start_date>
  <completion_date type="Actual">September 2011</completion_date>
  <primary_completion_date type="Actual">September 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum Glucose Infusion Rate (GIR) to maintain euglycemia</measure>
    <time_frame>Six hour observation period</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to Maximum Glucose Infusion Rate</measure>
    <time_frame>Six Hour Observation period</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">36</enrollment>
  <condition>Diabetes Mellitus, Type I</condition>
  <arm_group>
    <arm_group_label>Catheter day 4</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Adolescents with type 1 diabetes with catheters day #4</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Catheter day 1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Adolescents with type 1 diabetes with catheter day #1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Aspart and Detemir</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Adolescents with type 1 diabetes</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lispro and Glargine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Adolescents with type 1 diabetes</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Insulin analogs (Lispro and Aspart)</intervention_name>
    <description>Insulin bolus given through insulin pump</description>
    <arm_group_label>Catheter day 1</arm_group_label>
    <arm_group_label>Catheter day 4</arm_group_label>
    <other_name>Humalog, Novolog</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Insulin analogs (Aspart and Detemir)</intervention_name>
    <description>Drugs given separately</description>
    <arm_group_label>Aspart and Detemir</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Insulin analogs (Aspart and Detemir)</intervention_name>
    <description>Drugs given in the same injection</description>
    <arm_group_label>Aspart and Detemir</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Insulin analogs (Lispro and Glargine)</intervention_name>
    <description>Drugs given separately</description>
    <arm_group_label>Lispro and Glargine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Insulin analogs (Lispro and Glargine)</intervention_name>
    <description>Drugs given in single injection</description>
    <arm_group_label>Lispro and Glargine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age 8-17 (inclusive), of whom 15 will be prepubertal and 60 pubertal;&#xD;
&#xD;
          2. Clinical diagnosis of T1D (based on clinical presentation, insulin dependence,and/or&#xD;
             history of ketosis;&#xD;
&#xD;
          3. Diagnosis of T1D for at least one year's duration;&#xD;
&#xD;
          4. On CSII therapy for at least three months;&#xD;
&#xD;
          5. HbA1c 6.5-8.0%, inclusive;&#xD;
&#xD;
          6. Body mass index &lt; 95% for age and gender;&#xD;
&#xD;
          7. Meeting minimum weight requirement of at least 17.6 kg (for pre-pubertal subjects) or&#xD;
             34.6 kg (for pubertal subjects)&#xD;
&#xD;
          8. Ability to comprehend written and spoken English&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Any other medical disease aside from T1D or treated hypothyroidism&#xD;
&#xD;
          2. Receiving any other medication besides insulin or levothyroxine&#xD;
&#xD;
          3. Female subjects of reproductive potential who may be pregnant, breast feeding, or not&#xD;
             consistently utilizing barrier methods or abstinence as contraception&#xD;
&#xD;
          4. Inability to comprehend written and spoken English&#xD;
&#xD;
          5. Any other condition, which in the judgement of the investigators, would interfere with&#xD;
             the subject's or parents' ability to provide informed consent or the investigator's&#xD;
             ability to perform the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>8 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stuart A Weinzimer, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Yale University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Eda Cengiz, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Yale University</affiliation>
  </overall_official>
  <results_reference>
    <citation>Cengiz E, Swan KL, Tamborlane WV, Sherr JL, Martin M, Weinzimer SA. The alteration of aspart insulin pharmacodynamics when mixed with detemir insulin. Diabetes Care. 2012 Apr;35(4):690-2. doi: 10.2337/dc11-0732. Epub 2012 Feb 28.</citation>
    <PMID>22374642</PMID>
  </results_reference>
  <results_reference>
    <citation>Cengiz E, Tamborlane WV, Martin-Fredericksen M, Dziura J, Weinzimer SA. Early pharmacokinetic and pharmacodynamic effects of mixing lispro with glargine insulin: results of glucose clamp studies in youth with type 1 diabetes. Diabetes Care. 2010 May;33(5):1009-12. doi: 10.2337/dc09-2118. Epub 2010 Feb 11.</citation>
    <PMID>20150302</PMID>
  </results_reference>
  <results_reference>
    <citation>Swan KL, Dziura JD, Steil GM, Voskanyan GR, Sikes KA, Steffen AT, Martin ML, Tamborlane WV, Weinzimer SA. Effect of age of infusion site and type of rapid-acting analog on pharmacodynamic parameters of insulin boluses in youth with type 1 diabetes receiving insulin pump therapy. Diabetes Care. 2009 Feb;32(2):240-4. doi: 10.2337/dc08-0595. Epub 2008 Nov 18.</citation>
    <PMID>19017777</PMID>
  </results_reference>
  <results_reference>
    <citation>Swan KL, Weinzimer SA, Dziura JD, Steil GM, Voskanyan GR, Steffen AT, Martin ML, Tamborlane WV. Effect of puberty on the pharmacodynamic and pharmacokinetic properties of insulin pump therapy in youth with type 1 diabetes. Diabetes Care. 2008 Jan;31(1):44-6. Epub 2007 Oct 1.</citation>
    <PMID>17909083</PMID>
  </results_reference>
  <verification_date>August 2016</verification_date>
  <study_first_submitted>March 27, 2008</study_first_submitted>
  <study_first_submitted_qc>March 31, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 3, 2008</study_first_posted>
  <last_update_submitted>August 30, 2016</last_update_submitted>
  <last_update_submitted_qc>August 30, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 1, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Type I Diabetes Mellitus</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Insulin Glargine</mesh_term>
    <mesh_term>Insulin Aspart</mesh_term>
    <mesh_term>Insulin, Long-Acting</mesh_term>
    <mesh_term>Insulin degludec, insulin aspart drug combination</mesh_term>
    <mesh_term>Insulin Lispro</mesh_term>
    <mesh_term>Insulin Detemir</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

